Difficulty: Medium
Average Score: 67%
Practice
The following enzymes and inhibitors are matched correctly:
Correct answer
A
Rationale
In pediatric cardiovascular disorders nursing, understanding pharmacology is crucial for safe and effective patient care. In this question, the correct match is A) Xanthine oxidase-allopurinol. Xanthine oxidase is an enzyme involved in purine metabolism, and allopurinol is an inhibitor of this enzyme commonly used to treat conditions like gout. Allopurinol works by decreasing the production of uric acid, which can be beneficial in certain cardiovascular conditions.
Option B) Enolase-fluoride is incorrect because enolase is not a target for fluoride. Enolase is a glycolytic enzyme, while fluoride is known to inhibit enzymes like enolase in bacteria but not in the context of pediatric cardiovascular disorders.
Option C) Cholinesterase-physostigmine is incorrect because physostigmine is a cholinesterase inhibitor used in conditions like myasthenia gravis or anticholinergic toxicity, not in pediatric cardiovascular disorders where xanthine oxidase inhibitors are more relevant.
Option D) Ceruloplasmin-penicillamine is incorrect as ceruloplasmin is a copper-carrying protein, and penicillamine is used to chelate excess copper in conditions like Wilson's disease, not related to xanthine oxidase inhibition in pediatric cardiovascular disorders.
Educationally, this question highlights the importance of understanding the mechanisms of action of enzymes and inhibitors in pharmacology and their specific applications in pediatric cardiovascular disorders. By grasping these concepts, nurses can make informed decisions when administering medications and providing holistic care to pediatric patients with cardiovascular issues.
Option B) Enolase-fluoride is incorrect because enolase is not a target for fluoride. Enolase is a glycolytic enzyme, while fluoride is known to inhibit enzymes like enolase in bacteria but not in the context of pediatric cardiovascular disorders.
Option C) Cholinesterase-physostigmine is incorrect because physostigmine is a cholinesterase inhibitor used in conditions like myasthenia gravis or anticholinergic toxicity, not in pediatric cardiovascular disorders where xanthine oxidase inhibitors are more relevant.
Option D) Ceruloplasmin-penicillamine is incorrect as ceruloplasmin is a copper-carrying protein, and penicillamine is used to chelate excess copper in conditions like Wilson's disease, not related to xanthine oxidase inhibition in pediatric cardiovascular disorders.
Educationally, this question highlights the importance of understanding the mechanisms of action of enzymes and inhibitors in pharmacology and their specific applications in pediatric cardiovascular disorders. By grasping these concepts, nurses can make informed decisions when administering medications and providing holistic care to pediatric patients with cardiovascular issues.